logo-loader
viewKazia Therapeutics Ltd

Full interview: Kazia Therapeutics presents new data from Cantrixil Phase 1 Study in Ovarian Cancer at global conference

Kazia Therapeutics Ltd - Kazia Therapeutics presents new data from Cantrixil Phase 1 Study in Ovarian Cancer at global conference

Kazia Therapeutics Limited (ASX:KZA) chief executive officer Dr James Garner updates Proactive on the company’s presentation of new data from the Cantrixil Phase 1 Study in Ovarian Cancer, at the European Society for Medical Oncology (ESMO) in Barcelona, Spain.

The CEO also spoke about Kazia winning a award at the inaugural ANZLF Trans-Tasman Innovation & Growth Awards, with the $20,000 prize presented by New Zealand Prime Minister Jacinda Ardern. 

In other milestones, Dr Garner discussed important work Kazia is doing with the US-based St Jude’s Children’s Research Hospital into a rare and deadly form of childhood brain cancer, and how the World Health Organisation has selected a provisional name for the company’s lead drug GDC-0084.

Quick facts: Kazia Therapeutics Ltd

Price: 0.44 AUD

ASX:KZA
Market: ASX
Market Cap: $27.35 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Kazia Therapeutics releases new safety data to assist in brain cancer treatments

Kazia Therapeutics Ltd (ASX:KZA) chief executive officer James Garner speaks to Proactive Investors about new safety and tolerability data from the company's phase-IIa clinical trial of brain cancer treatment.    Garner said the superior results from the ongoing study of...

on 05/07/2019

2 min read